Celldex Therapeutics, Inc. Recap

What is your opinion of Celldex Therapeutics, Inc.?

Celldex Therapeutics, Inc.

NASDAQ:CLDX - Oct. 4th 4:56am

$ 11.88 1.31 (12.39%)

Shares of Celldex Therapeutics, Inc. – a $1.1 billion market cap Pharmaceuticals company – have risen 12.39 percent to $11.88 as of 12:00 AM.

Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Find out more about Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. Stock Price

Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded at a volume of 2.06 million shares. On average, Celldex Therapeutics, Inc. trades at a volume of 1.88 million shares.

HAMPTON, NJ | 2 days ago

Celldex Therapeutics, Inc.